BioPharmSignal logoBioPharmSignal

Biotech News

BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.Earnings

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-05-15 20:05 EST

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

ADXNAddex Therapeutics2026-06-25 05:00 EST

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

JSPRJasper Therapeutics2026-05-14 20:05 EST

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-05-11 11:00 EST

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

ADXNAddex Therapeutics2026-06-22 05:00 EST

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

PSTVPLUS THERAPEUTICS, Inc.2026-05-15 20:05 EST

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

IKTInhibikase Therapeutics2026-05-12 20:01 EST

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

View all latest news

Brainstorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics is a cell-therapy company focused on neurological disease, especially ALS. Its platform has long been tied to a high-risk, high-conviction neurodegeneration story.

Recent company news

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

BCLIBrainstorm Cell Therapeutics Inc.2026-06-02 13:00 EST

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BCLIBrainstorm Cell Therapeutics Inc.2026-05-28 11:45 EST

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

BCLIBrainstorm Cell Therapeutics Inc.2026-05-19 12:00 EST

BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

BCLIBrainstorm Cell Therapeutics Inc.2026-05-15 20:05 EST

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
0.80 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States